Literature DB >> 16418208

Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer.

Carmen Sáez1, M Asunción Martínez-Brocca, Carolina Castilla, Alfonso Soto, Elena Navarro, María Tortolero, José A Pintor-Toro, Miguel A Japón.   

Abstract

CONTEXT: Human securin pituitary tumor-transforming gene (hPTTG) is overexpressed in a variety of primary neoplasias, including differentiated thyroid cancer (DTC).
OBJECTIVE: The objective of this study was to examine the immunohistochemical expression of hPTTG in DTC and its association with known prognostic factors.
DESIGN: hPTTG expression was analyzed by immunostaining on paraffin-embedded tissues. Clinical data were used to determine any associations between the expression of hPTTG and prognostic variables of DTC. A median follow-up of 43 months allowed us to analyze the persistence of disease and the response to radioiodine therapy.
SETTING: The study was conducted at a tertiary university hospital. PATIENTS: Ninety-five patients undergoing surgical resection for DTC (n = 60) or benign nodular thyroid disease (n = 35) were studied. MAIN OUTCOME MEASURE: The main outcome measure was the association between hPTTG expression and prognostic factors in DTC.
RESULTS: Among DTC cases, 21 (35%) had low and 39 (65%) had high hPTTG immunostaining. Adjacent nonneoplastic thyroid tissue was largely unstained. Among benign nodular thyroid disease cases, immunostaining was detected focally in eight (22.8%). A significant association was found between hPTTG expression and the presence of nodal (P < 0.01) or distant metastases (P < 0.05). A significant association with TNM was also found, because 83.3% of advanced TNM stages showed elevated hPTTG (P < 0.05). The association between hPTTG overexpression and decreased radioiodine uptake during follow-up was also significant (P < 0.05). The expression levels of hPTTG were confirmed as an independent prognostic factor for persistent disease (relative risk, 3.0; 95% confidence interval, 1.1-8.7; P < 0.05).
CONCLUSIONS: Immunohistochemical analysis of hPTTG is of potential value in the determination of tumor aggressiveness in DTC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418208     DOI: 10.1210/jc.2005-2532

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Expression profile of DNA damage signaling genes in 2 Gy proton exposed mouse brain.

Authors:  Sudhakar Baluchamy; Ye Zhang; Prabakaran Ravichandran; Vani Ramesh; Ayodotun Sodipe; Joseph C Hall; Olufisayo Jejelowo; Daila S Gridley; Honglu Wu; Govindarajan T Ramesh
Journal:  Mol Cell Biochem       Date:  2010-04-11       Impact factor: 3.396

2.  Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.

Authors:  Mar Mora-Santos; M Cristina Limón-Mortés; Servando Giráldez; Joaquín Herrero-Ruiz; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

3.  Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins.

Authors:  Sudhakar Chintharlapalli; Sabitha Papineni; Syng-Ook Lee; Ping Lei; Un Ho Jin; Steven I Sherman; Libero Santarpia; Stephen Safe
Journal:  Mol Carcinog       Date:  2011-01-25       Impact factor: 4.784

Review 4.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

5.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.

Authors:  Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

6.  Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation.

Authors:  Agueda G Espina; Cristina Méndez-Vidal; Miguel A Moreno-Mateos; Carmen Sáez; Ana Romero-Franco; Miguel A Japón; José A Pintor-Toro
Journal:  Mol Biol Cell       Date:  2009-05-28       Impact factor: 4.138

Review 7.  The pituitary tumor transforming gene in thyroid cancer.

Authors:  G D Lewy; N Sharma; R I Seed; V E Smith; K Boelaert; C J McCabe
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

Review 8.  Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.

Authors:  Ji Min Oh; Byeong-Cheol Ahn
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

9.  PTTG1 attenuates drug-induced cellular senescence.

Authors:  Yunguang Tong; Weijiang Zhao; Cuiqi Zhou; Kolja Wawrowsky; Shlomo Melmed
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

Review 10.  Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.

Authors:  X Cai; R Wang; J Tan; Z Meng; N Li
Journal:  Clin Transl Oncol       Date:  2021-06-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.